Adirondack Trust Company’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.14M Sell
19,711
-350
-2% -$20.1K 0.34% 58
2026
Q1
$1.22M Sell
20,061
-3,104
-13% -$181K 0.41% 50
2025
Q4
$1.25M Sell
23,165
-203
-0.9% -$9.77K 0.41% 52
2025
Q3
$1.05M Sell
23,368
-334
-1% -$15.6K 0.35% 59
2025
Q2
$1.1M Sell
23,702
-1,890
-7% -$92.8K 0.4% 59
2025
Q1
$1.56M Sell
25,592
-556
-2% -$32.4K 0.61% 41
2024
Q4
$1.48M Sell
26,148
-779
-3% -$43.5K 0.56% 44
2024
Q3
$1.39M Sell
26,927
-639
-2% -$30K 0.54% 46
2024
Q2
$1.14M Sell
27,566
-314
-1% -$14.1K 0.47% 53
2024
Q1
$1.51M Sell
27,880
-575
-2% -$29.3K 0.63% 40
2023
Q4
$1.44M Sell
28,455
-1,047
-4% -$55K 0.62% 41
2023
Q3
$1.71M Sell
29,502
-149
-0.5% -$9.13K 0.85% 29
2023
Q2
$1.84M Sell
29,651
-1,509
-5% -$101K 0.86% 27
2023
Q1
$2.16M Sell
31,160
-258
-0.8% -$18.2K 1.09% 24
2022
Q4
$2.26M Buy
31,418
+117
+0.4% +$8.82K 1.17% 24
2022
Q3
$2.23M Buy
31,301
+2
+0% +$145 1.24% 21
2022
Q2
$2.41M Buy
31,299
+763
+2% +$58.1K 1.29% 20
2022
Q1
$2.23M Buy
30,536
+2,327
+8% +$156K 1.06% 24
2021
Q4
$1.76M Sell
28,209
-660
-2% -$38.7K 0.84% 32
2021
Q3
$1.69M Buy
28,869
+308
+1% +$20.3K 0.8% 32
2021
Q2
$1.91M Buy
28,561
+320
+1% +$20.9K 0.96% 25
2021
Q1
$1.78M Buy
28,241
+1,755
+7% +$109K 0.95% 23
2020
Q4
$1.63M Buy
26,486
+120
+0.5% +$7.38K 0.98% 22
2020
Q3
$1.59M Buy
26,366
+470
+2% +$28.3K 1.04% 23
2020
Q2
$1.52M Sell
25,896
-330
-1% -$19.7K 1% 23
2020
Q1
$1.46M Buy
26,226
+955
+4% +$58.4K 1.19% 22
2019
Q4
$1.59M Buy
25,271
+781
+3% +$44.7K 1.04% 25
2019
Q3
$1.24M Sell
24,490
-120
-0.5% -$5.64K 0.87% 30
2019
Q2
$1.12M Sell
24,610
-65
-0.3% -$3.03K 0.78% 34
2019
Q1
$1.15M Sell
24,675
-311
-1% -$15.5K 0.79% 34
2018
Q4
$1.3M Sell
24,986
-75
-0.3% -$4.03K 1.01% 27
2018
Q3
$1.56M Sell
25,061
-205
-0.8% -$12.2K 1.05% 25
2018
Q2
$1.4M Buy
25,266
+250
+1% +$13.5K 0.99% 26
2018
Q1
$1.3M Buy
25,016
+603
+2% +$38.8K 0.93% 31
2017
Q4
$1.5M Sell
24,413
-520
-2% -$32.5K 1.09% 24
2017
Q3
$1.59M Sell
24,933
-55
-0.2% -$3.21K 1.25% 23
2017
Q2
$1.39M Sell
24,988
-5,336
-18% -$290K 1.12% 24
2017
Q1
$1.65M Sell
30,324
-1,948
-6% -$107K 1.15% 23
2016
Q4
$1.89M Sell
32,272
-255
-0.8% -$13.9K 1.31% 20
2016
Q3
$1.75M Buy
32,527
+70
+0.2% +$4.5K 1.26% 18
2016
Q2
$2.39M Sell
32,457
-195
-0.6% -$13.8K 1.7% 14
2016
Q1
$2.09M Sell
32,652
-295
-0.9% -$18.6K 1.55% 16
2015
Q4
$2.05M Sell
32,947
-106
-0.3% -$7K 1.62% 16
2015
Q3
$1.96M Sell
33,053
-1,255
-4% -$79.6K 1.58% 16
2015
Q2
$2.28M Sell
34,308
-755
-2% -$49.8K 1.7% 14
2015
Q1
$2.26M Buy
35,063
+235
+0.7% +$14.7K 1.69% 13
2014
Q4
$2.06M Sell
34,828
-535
-2% -$30.2K 1.54% 16
2014
Q3
$1.81M Buy
35,363
+865
+3% +$43.2K 1.37% 19
2014
Q2
$1.67M Buy
34,498
+215
+0.6% +$10.6K 1.28% 23
2014
Q1
$1.78M Sell
34,283
-1,400
-4% -$74.5K 1.42% 17
2013
Q4
$1.9M Buy
35,683
+130
+0.4% +$6.62K 1.54% 16
2013
Q3
$1.65M Sell
35,553
-800
-2% -$35.1K 1.45% 18
2013
Q2
$1.62M Buy
+36,353
New +$1.58M 1.48% 18

Other funds holding BMY

Adirondack Trust Company's BMY Position: Q2 2026 in Review

Adirondack Trust Company reduced its Bristol-Myers Squibb (BMY) stake by 1.7% in Q2 2026, selling an estimated $20.1K and leaving 19,711 shares worth $1.14M. The position accounts for 0.34% of the portfolio, ranked #58.

Adirondack Trust Company first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.41M in Q2 2022. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Adirondack Trust Company held 19,711 shares of Bristol-Myers Squibb worth $1.14M as of Q2 2026.
  • Adirondack Trust Company sold 350 Bristol-Myers Squibb shares in Q2 2026, an estimated $20.1K.
  • Bristol-Myers Squibb made up 0.34% of Adirondack Trust Company's portfolio in Q2 2026, its #58 holding.
  • Adirondack Trust Company first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Adirondack Trust Company's Bristol-Myers Squibb position peaked at $2.41M in Q2 2022.
  • 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Adirondack Trust Company's 13F filing for Q2 2026, filed 16 Jul 2026.